Thank you for the opportunity to clarify on CanSino. There's a narrative out there about us recommending that we go with CanSino. I want to clarify the collaboration between NRC and CanSino was a research agreement. At no point that we're aware of was there any decision or discussion about preferentially procuring the CanSino vaccine to Canadians or having it as our preferred option. At that stage, it was a collaboration to carry out early phases—phases one and two clinical trials—in Canada. That was completely separate from the vaccine task force studies of international and domestic vaccines.
The timelines of the vaccine task force were somewhat comparable to what happened in the U.K. We started looking at memberships, vetting participants and everything around the month of April or May. In terms of the official announcement, that's another matter. The U.K. vaccine task force was announced in the month of May, so the timelines are comparable, I would say.